Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07502443
PHASE3

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

Sponsor: Alkermes, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.

Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 (Brilliance NT2 Study 303)

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

176

Start Date

2026-04

Completion Date

2027-06

Last Updated

2026-03-31

Healthy Volunteers

No

Interventions

DRUG

ALKS 2680 Dose 1

Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks

DRUG

ALKS 2680 Dose 2

Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks

DRUG

ALKS 2680 Dose 3

Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks

DRUG

Placebo

Participants will receive placebo tablets, daily, orally for 12 weeks